Biosimilar

Bio-Thera Solutions Expands Partnership with Biomm in Brazil with Addition of BAT2206, a Stelara® Biosimilar

Retrieved on: 
Friday, June 16, 2023
Biotechnology, Pharmaceutical, Health, Contraindication, Bevacizumab, Partnership, Radiation, Marketing, European Medicines Agency, Methotrexate, PUVA, Ulcerative colitis, Psoriasis, EMA, Psoriatic arthritis, Patient, National Medical Products Administration, Ciclosporin, Biosimilar, FDA, Ustekinumab, NMPA, Pharmaceutical industry

Bio-Thera and Biomm’s partnership was initiated around a licensing and supply agreement for Biomm to distribute and market BAT1706, a bevacizumab biosimilar, in Brazil.

Key Points: 
  • Bio-Thera and Biomm’s partnership was initiated around a licensing and supply agreement for Biomm to distribute and market BAT1706, a bevacizumab biosimilar, in Brazil.
  • This partnership will leverage Biomm’s strong local presence, sales and marketing capabilities in Brazil.
  • “Bio-Thera is pleased to expand our partnership with Biomm to commercialize our ustekinumab biosimilar program in Brazil”, said Dr. Shengfeng Li, CEO of Bio-Thera.
  • “By expanding our partnership with Biomm, Bio-Thera is doubling its commitment to providing Brazilian patients with increased access to important biotherapeutics at affordable prices.”

TELUS Health 2023 Drug Trends Report: Diabetes now the top drug category for claims; antidepressants surged for youth

Retrieved on: 
Tuesday, June 13, 2023
Insurance, Pharyngealization, Asthma, Depression, Urinary tract infection, Diabetes, Biosimilar, Infection, COVID-19, Weight loss, ADHD, Telus Health, Influenza, Pharmacy benefit management, Attention deficit hyperactivity disorder, RSV, Risk, Growth, PBM, Conditional sentence, Health, TELUS, Mental health, Rheumatoid arthritis, Inflammation, Pharmaceutical industry, Dietary supplement, Generic drug, Pharmacist

TORONTO, June 13, 2023 (GLOBE NEWSWIRE) -- Today, TELUS Health issued its annual 2023 Drug Data Trends and National Benchmarks Report , revealing that diabetes has replaced inflammatory diseases, such as rheumatoid arthritis, as the top drug category for claims in Canada.

Key Points: 
  • TORONTO, June 13, 2023 (GLOBE NEWSWIRE) -- Today, TELUS Health issued its annual 2023 Drug Data Trends and National Benchmarks Report , revealing that diabetes has replaced inflammatory diseases, such as rheumatoid arthritis, as the top drug category for claims in Canada.
  • “It is our hope that the findings in our 2023 Drug Trends Report will continue to offer private payors and benefits advisors valuable insights to help adjust and improve benefits plans,” said Martin Bélanger, Managing Director, Payor Solutions, TELUS Health.
  • “The fact that growth in spend has been observed in a specific diabetes class of drugs suggests that existing claimants are switching to more costly therapies,” noted Lavina Viegas, Pharmacist, TELUS Health.
  • Published annually since 2015, the TELUS Health Drug Data Trends and National Benchmarks Report is based on the claims data of the 2022 TELUS Health portfolio, and provides a contextual view of adoption rates of plan management trends to help insurers and employers alike understand major trends in prescription drug utilization.

American Oncology Network Announces List of Research Studies Presented at the ASCO 2023 Annual Meeting

Retrieved on: 
Tuesday, June 6, 2023
Abstract, The Center, Education, AON, Biosimilar, Breast, MBA, Research, Doctor of Philosophy, Pharmacist, Cornerstone, ASCO, MD, Chowdhury, Patient, Physician, B7-H4, Sarah Cannon Research Institute, ADC, Endometrium, Nursing, Pharmaceutical industry, Generic drug, Cancer

BELLWAVE-003: A phase 2 dose escalation, confirmation, and cohort expansion study of nemtabrutinib in hematologic malignancies (Abstract TPS7593 ).

Key Points: 
  • BELLWAVE-003: A phase 2 dose escalation, confirmation, and cohort expansion study of nemtabrutinib in hematologic malignancies (Abstract TPS7593 ).
  • XMT-1660: A phase 1b trial of a B7-H4 targeted antibody drug conjugate (ADC) in breast, endometrial, and ovarian cancers (Abstract TPS3154 ).
  • “I am proud that our abstract has been selected for discussion at this year’s ASCO annual meeting,” said Chang.
  • To have their studies featured at the ASCO Annual Meeting is an honor not only for them but for all of AON.”
    The ASCO Annual Meeting brings together today’s top leaders in healthcare.

HealthEZ Hires New Chief Revenue Officer as Momentum Continues to Grow

Retrieved on: 
Wednesday, June 7, 2023
General Health, Health, Professional Services, Insurance, Health Insurance, Arizona Health Care Cost Containment System, PPO, Biosimilar, Lead, Multimedia, Pharmacy, YOY, NSA, Investment, Growth, Eagle Cash, Online shopping, Sales, United States Army

HealthEZ is pleased to announce the hiring of Jim Wachtel as Chief Revenue Officer.

Key Points: 
  • HealthEZ is pleased to announce the hiring of Jim Wachtel as Chief Revenue Officer.
  • Jim will lead the sales, account management and marketing teams as the company continues to build upon strong 2022 performance and momentum.
  • With a strong background in health and benefits, I’m ready to jump in to lead and coach the growth teams at HealthEZ,” says Jim Wachtel, HealthEZ Chief Revenue Officer.
  • “Adding Jim to our high-powered executive team feels like putting an exclamation point on the success we experienced in our 40th year in business,” says Jeff Bakke, HealthEZ Chief Executive Officer.

Investor Open Day: Fosun Implements Business Streamlining and Resilience Building Strategy, Focusing on Core Businesses to Bring New Vitality

Retrieved on: 
Friday, June 9, 2023
Lanvin, Bank of Communications, BlackRock, CICC, GF Securities, European, UBS, Biosimilar, Relaxation, BLA, Mining, The Bund Finance Center, Carcinoma, China Construction Bank, Tourism, Bank of China, Face, Culture, Commercial bank, Yuyuan Tourist Mart, Innovation, Research, Agricultural Bank of China, FTG, Growth, FDA, Empowerment, S&P Global Ratings, Industrial and Commercial Bank of China, Club Med, Communication, Agricultural Bank, Health, J.P. Morgan & Co., BFC, Fosun Pharma, Industrial, Social services, S&P Global, Person, Bank, Annual report, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Security (finance), Management, Renewable energy, Pharmaceutical industry, Fine chemical, Fosun International, EU

It was the first time that Fosun International had held a large-scale offline open day after the pandemic.

Key Points: 
  • It was the first time that Fosun International had held a large-scale offline open day after the pandemic.
  • The investor relations team of Fosun International gave investors an in-depth tour of Fosun Pharma headquarters, the Grand Yuyuan, the Bund Finance Center (BFC), etc.
  • After winning out over the "perfect storm" in 2022, Fosun has been maintaining its strategic focus and accelerating the implementation of the business streamlining and core business-focused strategy.
  • As of the end of March 2023, Fosun successfully brought down holding-company debt by about RMB24.0 billion to RMB93.0 billion.

Rani Therapeutics and Celltrion Expand Partnership to Include Adalimumab Biosimilar for RT-105

Retrieved on: 
Monday, June 5, 2023
Injection, Partnership, Therapy, Adalimumab, SAN, Biosimilar, HC, Ustekinumab, Celltrion, Inflammation, Pharmaceutical industry

SAN JOSE, Calif., June 05, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has expanded its partnership with Celltrion by entering into an agreement for the development of RT-105, an orally administered adalimumab biosimilar.

Key Points: 
  • SAN JOSE, Calif., June 05, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has expanded its partnership with Celltrion by entering into an agreement for the development of RT-105, an orally administered adalimumab biosimilar.
  • Rani’s first partnership with Celltrion, for the development of RT-111, an orally administered ustekinumab biosimilar, was announced in January of this year.
  • Under the terms of the new license and supply agreement, Celltrion will exclusively supply to Rani the adalimumab biosimilar drug substance (CT-P17) required for RT-105.
  • “We are delighted to expand our partnership with Celltrion, a world-class pharmaceutical company, a leader in biosimilars and our valued partner,” said Talat Imran, CEO of Rani.

Spending on antidiabetic drugs in Canada outpaced overall drug market

Retrieved on: 
Tuesday, May 30, 2023
Patented Medicine Prices Review Board, PMPRB, Jalisco New Generation Cartel, Diabetes, Biosimilar, Policy, Market intelligence, Patient, Growth, Generic drug, Pharmaceutical industry, Insulin glargine, Atlantic Ocean

The Patented Medicine Prices Review Board (PMPRB), through the National Prescription Drug Utilization Information System (NPDUIS) research initiative, today published the latest edition of the Market Intelligence Report: Antidiabetic Drugs, 2012-2021, which examines the market for drugs used in the treatment of diabetes.

Key Points: 
  • The Patented Medicine Prices Review Board (PMPRB), through the National Prescription Drug Utilization Information System (NPDUIS) research initiative, today published the latest edition of the Market Intelligence Report: Antidiabetic Drugs, 2012-2021, which examines the market for drugs used in the treatment of diabetes.
  • This fourth report in the Market Intelligence series analyzes the market for drugs used in the treatment of diabetes.
  • Antidiabetic drug growth outpaced the overall drug market, effectively doubling the market share for these drugs from 4.2% to 7.9% (2012 to 2021).
  • These drugs were responsible for almost all of Canada's increase in cost per capita of antidiabetic drugs since 2012.

VIATRIS INC. (NASDAQ: VTRS) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Viatris Inc.

Retrieved on: 
Friday, May 26, 2023
LLP, District court, Investment, Advertising, Complaint, Court, Action Replay, Biosimilar, News, Pfizer, Tobacco, Generic drug, Cryptocurrency, Security (finance), Viatris

NEW YORK, May 26, 2023 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the common stock of Viatris Inc. (“Viatris” or the “Company”) (NASDAQ: VTRS) between March 1, 2021 and February 25, 2022, inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the Western District of Pennsylvania and alleges violations of the Securities Exchange Act of 1934 against the Company and certain of its officers (the "Complaint").

Key Points: 
  • Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
  • NEW YORK, May 26, 2023 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the common stock of Viatris Inc. (“Viatris” or the “Company”) (NASDAQ: VTRS) between March 1, 2021 and February 25, 2022, inclusive (the “Class Period”).
  • The Company touts that its portfolio includes more than 1,400 approved molecules across a wide range of key therapeutic areas.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

Alvotech and Advanz Pharma extend strategic partnership to commercialize five proposed biosimilars in Europe

Retrieved on: 
Wednesday, May 24, 2023
Partnership, Omalizumab, Gross metropolitan product, Advanz Pharma, Patient, European Economic Area, Growth, Biosimilar, Fine chemical, Generic drug, IQVIA

Alvotech will be responsible for development and commercial supply and Advanz Pharma will be responsible for registration and commercialization in Europe.

Key Points: 
  • Alvotech will be responsible for development and commercial supply and Advanz Pharma will be responsible for registration and commercialization in Europe.
  • "We are very excited to extend our existing partnership with Advanz Pharma into additional therapeutic areas.
  • “This partnership positions Advanz Pharma as a key future player in European biosimilars.
  • In February 2023 Alvotech and Advanz Pharma announced that the companies had entered into an exclusive agreement for the commercialization of AVT23, a proposed biosimilar to Xolair® (omalizumab).

Celltrion USA Announces U.S. FDA Approval of Yuflyma® (adalimumab-aaty), a High-Concentration and Citrate-Free Formulation of Humira® (adalimumab) Biosimilar

Retrieved on: 
Wednesday, May 24, 2023
FDA, Health, Other Science, Pharmaceutical, Science, Biotechnology, Adalimumab, University of Massachusetts, Pharmacokinetics, Ankylosing spondylitis, Ulcerative colitis, Psoriasis, Juvenile idiopathic arthritis, Patient, Biosimilar, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, Celltrion, Food, Rheumatoid arthritis, Inflammation, Pharmaceutical industry

Celltrion USA today announced that the U.S. Food and Drug Administration (FDA) has approved Yuflyma® (adalimumab-aaty), a high-concentration (100mg/mL) and citrate-free formulation of Humira® (adalimumab) biosimilar.

Key Points: 
  • Celltrion USA today announced that the U.S. Food and Drug Administration (FDA) has approved Yuflyma® (adalimumab-aaty), a high-concentration (100mg/mL) and citrate-free formulation of Humira® (adalimumab) biosimilar.
  • “Yuflyma offers patients a high-concentration and citrate-free formulation of adalimumab biosimilar, providing an alternative treatment option for patients.
  • It represents a key treatment option in patient care and patient choice,” said Tom Nusbickel, Chief Commercial Officer at Celltrion USA.
  • Celltrion is also seeking an interchangeability designation from the U.S. FDA for Yuflyma, which is tentatively expected Q4 2024.